(Q46366067)

English

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

0 references

author name string

Michallet AS

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Nicolini F

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Fürst S

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Le QH

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Dubois V

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Hayette S

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Bourgeot JP

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Tremisi JP

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Thomas X

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Gebuhrer L

10

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Michallet M

11

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

language of work or name

0 references

publication date

1 March 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

35

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

601-608

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

Donor lymphocyte infusions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplant: where we now stand.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and posttransplantation factors on outcome.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3(+) and CD4(+) lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

21 January 2018

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de Moelle (SFGM)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Graft-versus-tumor induction with donor leukocyte infusions as primary therapy for patients with malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Interleukin-2 after autologous stem cell transplantation for hematologic malignancy: a phase I/II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Human recombinant GM-CSF in allogeneic bone-marrow transplantation for leukaemia: double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term safety of GM-CSF (molgramostim) administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year follow-up of a double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704807

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BMT.1704807

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15756285

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46366067&oldid=2207820622"